Tectonic Therapeutic Inc. (NASDAQ: TECX) completed enrollment in its APEX Phase 2 clinical trial evaluating TX45 in patients with pulmonary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE